You are here

Our science / Clinical Trials / Find a Trial / NCT00230763

Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

Back to Search Print Save as PDF Bookmark Trial

NCT00230763

Last updated on May 12, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Agen, , 47000 France
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Primary Open Angle (POAG) Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female patients,

- Aged > than equal to 18 years,

- Patient presenting with an OHT or OAG with an IOP � 21 mmHg,

- Patient currently treated with ophthalmic beta-blockers monotherapy and requiring a
change of the ophthalmic medication due to insufficient response to treatment,

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patient currently treated by or having received within the last month any ophthalmic
hypotensive agent other than a beta-blocker,

- Patient presenting any contraindication to latanoprost or timolol,

- Patient with history of asthma, obstructive broncho-pneumopathy, sinusal bradycardia
(pulse rate disease or any other condition that would preclude the patient from taking the
prescribed medication,

- Patient with known intolerance to benzalkonium chloride or any excipient contained in
the trial treatment,

NCT00230763
Pfizer
Completed
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Partial Seizures Epilepsy, Primary Generalized Tonic-Clonic Seizures Epilepsy
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306
All Genders
0+
Years
Multiple Sites
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Open-Angle Glaucoma, Ocular Hypertension
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
NCT00159653
All Genders
18+
Years
Multiple Sites
Hypertension
Treatment of Pediatric Hypertension With Altace Trial
NCT00044265
All Genders
6+
Years
Multiple Sites
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Ocular Hypertension
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT, concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal thickness, compliance, and adverse events).
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Glaucoma, Primary Open Angle (POAG)
  • Ocular Hypertension
  • Procedure: GSS questionnaire
    D0, D30 and D84
  • Procedure: IOP
    D0, D30 and D84
  • Drug: LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
    in the evening during 84 days
    Other Name: XALACOM
  • Procedure: Visual acuity
    D0 and D84
  • Experimental: Active
    Intervention: Drug: LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
  • Procedure
    Interventions:
    • Procedure: GSS questionnaire
    • Procedure: IOP
    • Procedure: Visual acuity
Sellem E, Rouland JF, Baudouin C, Bron A, Denis P, Nordmann JP, Renard JP. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination. BMC Ophthalmol. 2010 Mar 26;10:10. doi: 10.1186/1471-2415-10-10.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
396
October 2007
October 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients,
  • Aged > than equal to 18 years,
  • Patient presenting with an OHT or OAG with an IOP ? 21 mmHg,
  • Patient currently treated with ophthalmic beta-blockers monotherapy and requiring a change of the ophthalmic medication due to insufficient response to treatment,

Exclusion Criteria:

  • Patient currently treated by or having received within the last month any ophthalmic hypotensive agent other than a beta-blocker,
  • Patient presenting any contraindication to latanoprost or timolol,
  • Patient with history of asthma, obstructive broncho-pneumopathy, sinusal bradycardia (pulse rate < 60 bpm), auriculo-ventricular block, cardiac insufficiency, Raynaud disease or any other condition that would preclude the patient from taking the prescribed medication,
  • Patient with known intolerance to benzalkonium chloride or any excipient contained in the trial treatment,
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00230763
A6641040
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now